Celltrion Inc
π§πͺBelgium
- Country
- π§πͺBelgium
- Ownership
- -
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- $31.9B
- Website
- http://www.celltrion.com/
An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 302
- Registration Number
- NCT01571219
- Locations
- π°π·
Hanyang University Medical Center, Seoul, Korea, Republic of
Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 154
- Registration Number
- NCT01534884
- Locations
- π°π·
Hanyang University Medical Center, Seoul, Korea, Republic of
Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 1
- Registration Number
- NCT01534949
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 257
- Registration Number
- NCT01220518
- Locations
- π°π·
Inha University Hostpital, Incheon, Korea, Republic of
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 617
- Registration Number
- NCT01217086
- Locations
- π°π·
Hanyang University Medical Center, Seoul, Korea, Republic of
Evaluate Safety, Efficacy and Pharmacokinetics
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 174
- Registration Number
- NCT01084863
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Demonstrate Efficacy and Safety of Metastatic Breast Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 475
- Registration Number
- NCT01084876
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Β© Copyright 2024. All Rights Reserved by MedPath